The British Medical Journal (BMJ) Case Reports journal has reported that a healthy 16-year-old Australian girl lost all ovarian function and went into menopause after being injected with the human papilloma virus (HPV) vaccine Gardasil.
Dr. Deirdre Little, the Australian physician who treated the girl, provides solid evidence that Gardasil caused the destruction of the girl’s fertility.
She also pointed out that Merck Pharmaceutical, the manufacturer of Gardasil, has no supporting information on the effects of the vaccine on ovaries, suggesting that Merck had either done no safety testing on Gardasil in relation to its effects on women’s reproductive systems, or had suppressed the information.
The girl received the Gardasil vaccination in the fall of 2008. By January 2009, her cycle had become irregular. Over the course of the next two years, her menses became increasingly scant and irregular, until by 2011, she had ceased menstruating altogether.
“This patient presented with amenorrhoea after identifying a change from her regular cycle to irregular and scant periods following vaccinations against human papillomavirus,” Dr. Little wrote in the report.
Dr. Little carried out numerous tests on the girl, including checking hormone levels and internal organ function, and diagnosed her as having “premature ovarian failure.” She also found that the girl had no living egg cells.
After investigating other possible causes of the girl’s premature ovarian failure, Dr. Little was left with the Gardasil vaccination as the only remaining explanation.
“Although the cause is unknown in 90% of cases, the remaining chief identifiable causes of this condition were excluded. Premature ovarian failure was then notified as a possible adverse event following this vaccination,” Dr. Little stated.
In the report titled “Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination,” Little wrote that Merck had only tested Gardasil’s effects on the testes of rats.
Dr. Little contacted the Therapeutic Goods Administration (TGA) of Australia, the equivalent of the U.S. Food and Drug Administration (FDA), for information about the safety testing of Gardasil on women’s ovaries.
She found that the TGA had records of various tests on rat testes, but no records of the effect of the vaccine on rat ovaries in the Australian Public Assessment Report for Human Papillomavirus Quadrivalent Vaccine (Gardasil).
Dr. Little’s report states that, “It is not known whether this event of premature ovarian failure is linked to the quadrivalent HPV vaccine. More detailed information concerning rat ovarian histology and ongoing fecundity post-HPV vaccination was sought from the Therapeutic Goods Administration (TGA).”
It revealed that “no histological report has been available for vaccinated rat ovaries.”
In other words, the TGA had no safety information on the effect of Gardasil on female reproductive systems.
“This event could hold potential implications for population health and prompts further inquiry,” Dr. Little’s report concluded.
“Gardasil has been controversial from the beginning,” noted Steven Mosher of the Population Research Institute.
Read more at: